ANALYSIS: Ozempic Claims Shoot Up, but for How Long?

July marked the beginning of the first wave of Ozempic-related pharmaceutical liability case filings, and as of August, it shows no signs of slowing down. This shouldn’t come as a surprise—the writing was on the wall after the popular weight loss drug’s spike in popularity was followed by reports of stomach-churning side effects. But while it’s still early days, pharmaceutical litigation trends from the past couple of years suggest that Ozempic won’t spur as much litigation as other recently litigated pharmaceutical products.

From Jan. 1 to Aug. 31, 854 complaints have been filed against Novo Nordisk—Ozempic’s manufacturer—in federal courts ...